Yaniv Erlich
Chief Executive Officer Eleven Therapeutics
Dr. Yaniv Erlich is the co-founder and CEO of Eleven Therapeutics. Prior to this position, he was the CSO of MyHeritage, a consumer genomics company (acquired by Francisco Partners), an Associate Professor of Computer Science at Columbia University and a Principal Investigator at the Whitehead Institute, MIT. Dr. Erlich received his bachelor’s degree from Tel-Aviv University, Israel (2006) and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory (2010). Dr. Erlich’s research interests are computational human genetics. Dr. Erlich is a TEDMED speaker (2018), the recipient of DARPA’s Young Faculty Award (2017), the Burroughs Wellcome Career Award (2013), Harold M. Weintraub award (2010), the IEEE/ACM-CS HPC award (2008), and he was selected as one of 2010 Tomorrow’s PIs team of Genome Technology.
Seminars
- Exploring the role of DELiveri® as a powerful product engine to enable functional screens of millions of delivery molecules in human cells in a one-pot reaction, for improved specificity of RNAi therapies
- Evaluating the quantitative output of the screen, providing a score for each molecule, and setting the basis to train AI algorithms
- Sharing insights from over 30 screens conducted across multiple primary human cell types, along with in-vivo validation data for novel compounds, to establish a robust predictive framework for translating in vitro results into effective in vivo therapies
